FIVE ALTERNATIVES TO VACCINES
May 06, 2020
1 minute
The enzyme inhibitor
Remdesivir is the frontrunner in the trial. It was originally developed by US biotechnology company Gilead Sciences to treat Ebola. It inhibits an enzyme called ‘RNA-dependent RNA polymerase’ that viruses need to replicate. A study in 2017 showed thatsaid that his condition improved the next day.
You’re reading a preview, subscribe to read more.
Start your free 30 days